Menlo Park, CA September 21, 2022 ( PR.com ) Life Science Strategy Group (LSSG), the leading strategic consulting firm to the CRO, CDMO and Biopharmaceutical industries, is pleased to announce
Updated Findings of COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report
2021 Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing and Changes Since 2020 Menlo Park, CA, May 25, 2021 (PR.com) Life Science Strategy Group (LSSG), the leading strategic consulting firm to the CRO industry, is pleased to announce the launch of its new syndicated report, COVID-19 Impact on the Biopharmaceutical Industry and CRO Outsourcing – 2021 Update. This updated study with 120 biopharmaceutical industry clinical development outsourcing decision makers in the US, Europe and China provides quantitative analysis, metrics, and insights into biopharmaceutical clinical development budgets, activity, outsourcing to CROs and outlook in 2021 vs. the same period in 2020.